Results 41 to 50 of about 4,817 (129)
CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.A cross‐database analysis of FAERS and JADER confirmed lamotrigine and zonisamide as the dominant SJS/TEN/DRESS risk drivers across both systems. After polytherapy adjustment, eslicarbazepine (DRESS, ROR 10.41) and levetiracetam emerged as reproducible novel signals warranting clinical attention. SJS/TEN onset concentrated within 4 weeks, whereas DRESS
Longfei You +4 more
wiley +1 more source
Neonatal Seizures in Tuberous Sclerosis Complex: A Case Series
Annals of the Child Neurology Society, Volume 4, Issue 2, Page 145-149, June 2026.ABSTRACT Background Epilepsy affects up to 90% of patients with tuberous sclerosis complex (TSC); earlier seizure onset is associated with worse neurocognitive outcomes. The incidence of neonatal seizures in TSC is unknown, although in a recent multicenter trial 23% of infants with TSC were excluded prior to randomization because of pre‐existing ...
Kristina Jülich, Kristen Arredondo
wiley +1 more source
Epileptic Disorders, Volume 28, Issue 3, Page 855-867, June 2026.Abstract Objectives Antiseizure medications (ASMs) can induce the activity of drug‐metabolizing enzymes and drug transporters, including cytochrome P450 (CYP)2C9 and P‐glycoprotein (P‐gp). Our objective was to comparatively assess the effects of ASMs on exposure to clinical CYP2C9 and P‐gp substrates.
Hagar Cohen +4 more
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.
Bruno Antunes Contrucci +10 more
wiley +1 more source
Self‐limited neonatal epilepsy with 2q24.3 duplications: Case series and literature review
Epileptic Disorders, Volume 28, Issue 3, Page 878-883, June 2026.Abstract Objective To clarify the phenotypic spectrum associated with duplications involving the 2q24.3 region, which includes a cluster of genes encoding sodium channel subunits (SCN1A, SCN2A, SCN3A, SCN7A, and SCN9A). Methods We reviewed our research database for patients with epilepsy and 2q24.3 duplication and performed thorough phenotyping.
Saba Al Rawahi, Kenneth A. Myers
wiley +1 more source
Clozapine for treatment‐resistant schizophrenia with epilepsy: A case report
Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.Clozapine (CLOZ) is often avoided in treatment‐resistant schizophrenia with comorbid epilepsy due to seizure risks. We report a successful case managed through a cautious CLOZ titration guided by multimodal monitoring, including clinical scales and blood tests such as C‐reactive protein (CRP), CLOZ levels, and anti‐seizure medication (ASM) levels ...
Toru Horinouchi +5 more
wiley +1 more source
Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.ABSTRACT Syntaxin‐binding protein 1 (STXBP1) mutations lead to severe epilepsy, intellectual disability, developmental delay, and movement disorder. Effective treatments for these conditions do not exist. Recent studies in Munc18‐1 (STXBP1) C. elegans models demonstrate that 4‐phenylbutyrate (4‐PBA) or related pharmacological chaperones stabilize ...
Aline Frick +2 more
wiley +1 more source
ChemMedChem, Volume 21, Issue 10, 27 May 2026.We developed a targeted covalent inhibitor for the p300/CBP‐associated factor (PCAF) bromodomain. Our lead molecule, 10, labeled a unique lysine residue in the PCAF bromodomain, demonstrated potent inhibition in biophysical/biochemical assays, and engaged the PCAF bromodomain in cells.
Richard R. Ede +9 more
wiley +1 more source
Correction: Analysis of treatment outcome variations in infantile epileptic spasms syndrome. [PDF]
Front NeurolGong X +7 more
europepmc +1 more source